Aquestive Therapeutics Inc., a pharmaceutical company based in Warren, announced it has appointed Gary H. Slatko as senior vice president, chief medical officer.
Slatko will be responsible for heading clinical and medical affairs for the company. He will report directly to CEO Keith J. Kendall.
“We are pleased to have Dr. Slatko join Aquestive and further our work in improving medications and outcomes for patients,” Kendall said. “Dr. Slatko’s experience at the FDA and in the pharmaceutical industry will benefit Aquestive’s entire proprietary pipeline.”
Prior to Aquestive, Slatko was a director in the Office of Medication Error Prevention and Risk Management at the U.S. Food and Drug Administration. Before that, he was chief medical officer of ParagonRx. He’s also spent time at Squibb, DuPont Merck, AstraZeneca and GlaxoSmithKline.
“I am truly excited to join Aquestive,” Slatko said. “Aquestive is at an important moment in its growth, and I look forward to working alongside my new colleagues to help further their goal of bringing differentiated treatments to patients.”
